Navigation Links
Fentanyl Narcotic Pain Patch under Scrutiny

Fentanyl skin patches (brand name Duragesic) a potent narcotic medication for pain management// is under FDA scrutiny after reports of deaths in patients using the patch were reported. The FDA says it is conducting an investigation into the deaths associated with these patches as it is unclear if the deaths are due to inappropriate use of the patch or factors related to the quality of the product.

Deaths and overdoses have occurred in patients using both the brand name product Duragesic and the generic product fentanyl. FDA officials say that the directions for using the fentanyl skin patch must be followed exactly to prevent death or other serious side effects from overdosing associated with fentanyl. They also say that some patients and doctors may not be fully aware of the dangers of this very strong narcotic painkiller; hence they feel the need to highlight important safety information about the drug which could benefit both patients and doctors . Some of the signs of overdose associated with fentanyl skin patch include shallow breathing; tiredness, extreme sleepiness, or sedation; inability to think, talk, or walk normally; and feeling faint, dizzy, or confused. FDA officials warn that if these signs occur, patients or their caregivers should get medical attention right away.

Page: 1

Related medicine news :

1. UN Report Paints Alarming Picture Of Narcotics Scenario In NE
2. Long-Term Narcotics Use for Back Pain May Be Ineffective and Lead to Abuse
3. FDA Approves Birth Control Skin Patch
4. Estrogen Patch is Safer than Pills for Heart
5. Painkilling Patch As Effective As Intravenous Delivery Systems
6. Testosterone Patches Found To Increase Sexual Desire In Menopausal Women
7. FDA Warns Against Birth-Control Patch
8. Nicotine Patches help to quit smoking
9. Reliable Help For Smokers From Nicotine Patches and Former Smokers
10. Increased Risk of Clot with Birth-Control Patch
11. Skin Patch Offers Relief to Patients with Parkinsons disease
Post Your Comments:

(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: